PARTICIPATION AGREEMENTParticipation Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • New York
Contract Type FiledMarch 12th, 2010 Company Industry JurisdictionThis Participation Agreement (this “Agreement”) is entered into as of the 22nd day of December, 2006 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”) and Philips Medical Systems Nederland B.V. a company having offices at Veenpluis 4-6, 5684 PC Best, the Netherlands (“Philips” and “Participant”); each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).
SUPPLY AGREEMENTSupply Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • Delaware
Contract Type FiledMarch 12th, 2010 Company Industry JurisdictionPayment to Corgenix for CE-Marking Services is estimated to be $[***] based on details provided in the Proposal dated December 15, 2008.
Research CollaborationResearch Collaboration Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories
Contract Type FiledMarch 12th, 2010 Company IndustryThis Agreement is entered into effective on this 20th day of January, 2010 (the “Effective Date”) by and between MERCK SHARP & DOHME CORP (formerly Merck & Co., Inc.), having offices at One Merck Drive, Whitehouse Station, NJ 08889 (hereinafter referred to as, “Merck”), and BG MEDICINE, INC., a private diagnostic development services company having offices at 610 Lincoln Street, Waltham, MA 02451 (“BGM”). Hereinafter, Merck and BGM are individually referred to as a “Party,” collectively as the “Parties”.
Participation AgreementParticipation Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • New York
Contract Type FiledMarch 12th, 2010 Company Industry JurisdictionThis Participation Agreement (this “Agreement”) is entered into as of the 31st day of March, 2008 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”) and Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka 540- 8645, Japan (“Participant”; each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).
PARTICIPATION AGREEMENTParticipation Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories • New York
Contract Type FiledMarch 12th, 2010 Company Industry JurisdictionThis Participation Agreement (this “Agreement”) is entered into as of the 28th day of July, 2006 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451 (“BGM”) and Merck & Co., Inc., having offices at One Merck Drive, Whitehouse Station, NJ 08889 (“Participant”; each of Participant and BGM are sometimes referred to individually as a “Party” and collectively as the “Parties”).
CONFIDENTIAL FIRST AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENTGalectin-3 License and Distribution Agreement • March 12th, 2010 • BG Medicine, Inc. • Services-medical laboratories
Contract Type FiledMarch 12th, 2010 Company IndustryTHIS FIRST AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “First Amendment”) is entered into as of February 3, 2010 (the “First Amendment Date”) by and between Abbott Laboratories, a corporation of the state of Illinois, having its principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610 Lincoln Street North, Waltham, Massachusetts 02451 (“BGM”).